CVS says specialty drug spend to quadruple

Share this article:
CVS say specialty drug spend to quadruple
CVS say specialty drug spend to quadruple

CVS/Caremark, the PBM, presented another perspective on the industry's increased focus on specialty medications: cost.

The pharmacy drug benefit manager projected consumer spending on treatments for diseases including cancer, immune deficiencies and multiple sclerosis will total $402 billion a year by 2020, a four-fold increase. While drug development does not necessarily trigger use, IMS Health's projections veer in the same direction: the research firm expects oncology drug sales will be between $74 billion and $84 billion in developed markets by 2017. As noted by IMS and CVS, specialty drugs usually require add-on costs, like being administered in a hospital or at a doctor's office.

CVS noted that specialized medicines are of particular note because only 4% of patients are responsible for the expected $402 billion in specialty medications costs. To tamp down on costs, CVS recommends implementing step-therapy requirements in which patients must first try lower-cost interventions before jumping to high-priced therapies.

Because treatment costs vary by field, eliminating a type of treatment—for example, infusions or all-oral therapies —will not reduce costs. Among the examples: oral MS drug Tecfidera costs $56,000 a year, and infused MS drug Tysabri rolls in at $53,000 a year, whereas infused cancer drug Herceptin costs $70,000 compared to the oral Gleevec, which costs $92,000 annually.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...